Vertex Pharmaceuticals (NASDAQ:VRTX) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 4 | 4 | 0 | 1 |
| Last 30D | 0 | 0 | 0 | 0 | 1 |
| 1M Ago | 2 | 1 | 1 | 0 | 0 |
| 2M Ago | 2 | 1 | 2 | 0 | 0 |
| 3M Ago | 1 | 2 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $474.86, a high estimate of $555.00, and a low estimate of $376.00. This current average has increased by 6.67% from the previous average price target of $445.15.
Investigating Analyst Ratings: An Elaborate Study
Login or create a forever free account to read this news
Sign up/Log in